{
  "abstract": "Viruses are no longer used merely as naturally occurring tools for gene transfer or as blunt cytolytic agents. Researchers are rewriting their genomes, capsids, tropisms, regulatory elements, and payloads to create therapeutic systems that sense disease, execute conditional programs, and remodel pathological tissue. In oncology, engineered oncolytic viruses (OVs) can combine tumor-selective replication with immunogenic cell death, antigen release, and local immune stimulation. In parallel, viral-vector engineering, particularly AAV and LVs, is addressing central limitations of gene delivery: the prevalence of pre-existing neutralizing antibodies, the difficulty of systemic administration and repeat dosing (AAV), and the manufacturing bottleneck of ex vivo cell therapies (LV). The clinical record is encouraging but uneven: T-VEC has shown that an engineered herpes simplex virus can improve durable responses in selected melanoma lesions, while G47Δ/teserpaturev and newer armed HSV platforms provide evidence of feasibility, safety, and occasional durable responses in difficult solid tumors. Lentiviral vector-based in vivo CAR-T cell generation, exemplified by KLN-1010/inMMyCAR and related first-in-human programs, signals a paradigm shift away from ex vivo manufacturing. However, the broader field has not converted its large preclinical literature into a proportional number of clinically meaningful, systemically deployable medicines. The main bottlenecks remain delivery, tumor heterogeneity, immune clearance, suboptimal pharmacodynamic biomarkers, manufacturing complexity, resistance, and the difficulty of proving benefit for products with delayed or immunologically mediated effects. This review examines the synthetic biology toolkit for programmable viral therapeutics through a unified engineering framework that integrates OVs, AAV, and LVs by design principle rather than by vector class. We discuss tumor-selective promoters, microRNA detargeting, retargeted capsids and ligands, attenuation, genome-scale assembly, immune-stimulatory payloads, bispecific and trispecific engagers, logic-gated circuits, safety switches, serodivergent AAV capsids, biomimetic cloaking, cell carriers, biomaterial delivery systems, and in vivo CAR-T generation. Our central thesis is that the next generation of viral medicines will be selected not by the most elaborate genome, but by the most coherent alignment of five measurable success factors: tumor selectivity, immune remodeling, delivery and biodistribution, controllable safety, and manufacturability. The emerging paradigm is therefore programmable viral therapeutics: context-sensitive biological medicines designed to operate within the constraints of human tumors and human immunity.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University P.O. Box 566 Irbid 21163 Jordan",
    "College of Pharmacy, RAK Medical and Health Sciences University Ras Al Khaimah United Arab Emirates",
    "Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University Zarqa 13133 Jordan",
    "Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University P.O. Box 566 Irbid 21163 Jordan",
    "Department of Biology and Biotechnology, Faculty of Science, The Hashemite University Zarqa Jordan",
    "School of Pharmaceutical Sciences, Lovely Professional University Phagwara 144411 India",
    "School of Bioengineering and Biosciences, Lovely Professional University Phagwara 144411 India",
    "College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University Ras Al Khaimah United Arab Emirates"
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Rawan H. Alsharedeh",
      "orcid": "0000-0003-2510-8109"
    },
    {
      "affs": [
        0
      ],
      "name": "Alaa A. A. Aljabali",
      "orcid": "0000-0002-9519-6338"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Mohammad A. Obeid"
    },
    {
      "affs": [
        2
      ],
      "name": "Abdelrahim Alqudah"
    },
    {
      "affs": [
        3
      ],
      "name": "Omar Gammoh"
    },
    {
      "affs": [
        4
      ],
      "name": "Esam Qnais"
    },
    {
      "affs": [
        5
      ],
      "name": "Vijay Mishra",
      "orcid": "0000-0001-6542-2464"
    },
    {
      "affs": [
        6
      ],
      "name": "Yachana Mishra",
      "orcid": "0000-0002-3467-0518"
    },
    {
      "affs": [
        7
      ],
      "name": "Mohamed El-Tanani"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/acfqj8fcfv90x.bib",
  "cited_by": 0,
  "doi": "10.1039/d6ra09938f",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13747162/",
  "id": "acfqj8fcfv90x",
  "issns": [
    "2046-2069"
  ],
  "landing_url": "https://doi.org/10.1039/d6ra09938f",
  "language": "en",
  "licence": "CC-BY-NC-3.0",
  "licence_label": "CC BY-NC 3.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/3.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Chemistry"
    ],
    [
      "openalex",
      "1311|Virus-based gene therapy research"
    ]
  ],
  "openalex": "W7225648891",
  "pdf_url": "https://europepmc.org/articles/PMC13747162?pdf=render",
  "pmcid": "PMC13747162",
  "pmid": "43005928",
  "published": "2026-11-09",
  "publisher": "Royal Society of Chemistry",
  "ris": "https://research.draconitic.com/paper/acfqj8fcfv90x.ris",
  "sources": [
    {
      "first_seen": "2026-11-11T12:24:19Z",
      "native_id": "PMC13747162",
      "source": "pmc",
      "url": "https://doi.org/10.1039/d6ra09938f"
    },
    {
      "first_seen": "2026-11-12T15:21:47Z",
      "native_id": "MED:43005928",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/43005928"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:1311|Virus-based gene therapy research",
      "subfield": "genetics-genomics"
    }
  ],
  "title": "The synthetic biology frontier: engineered oncolytic viruses and viral vectors for next-generation cancer therapy and gene delivery",
  "title_text": "The synthetic biology frontier: engineered oncolytic viruses and viral vectors for next-generation cancer therapy and gene delivery",
  "type": "peer-reviewed",
  "updated_at": "2026-11-13T12:23:55Z",
  "url": "https://research.draconitic.com/paper/acfqj8fcfv90x",
  "venue": "RSC Advances",
  "versions": []
}